CoChat

A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study

Biederman, Joseph, Mick, Eric, Faraone, Stephen, Hammerness, Paul, Surman, Craig, Harpold, Theresa, Dougherty, Meghan, Aleardi, Megan, Spencer, Thomas · 2006 · Journal of Clinical Psychopharmacology
Cited by 37

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Galantamine hydrogen bromide (HBr) is a competitive and reversible inhibitor of acetylcholinesterase. Because of its cholinergic nicotinic mechanism of action, galantamine HBr was hypothesized to have therapeutic activity in the treatment of attention-deficit/hyperactivity disorder (ADHD). METHOD: We conducted a 12-week, double-blind, placebo-controlled, randomized clinical trial using daily doses of up to 24 mg/d of galantamine HBr in the treatment of adults who met full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD with childhood-onset and persistent adult symptoms. All analyses were intention to treat with the last observation carried forward for subjects who did not complete the full study schedule. RESULTS: The mean daily doses at week 12 were 19.8 +/- 6.4 mg for galantamine HBr and 21.8 +/- 4.6 mg for placebo (P = 0.3). There was no statistically or clinically significant greater reduction in ADHD symptoms in subjects treated with galantamine HBr relative to those receiving placebo (P = 0.5). Using last observation carried forward, 4 (22%) of 18 of patients receiving galantamine HBr were considered responders (much or very much improved on the Clinical Global Impression Improvement Scale and at least a 30% reduction on the ADHD Investigator Symptom Report Scale compared with 11% [2/18] on placebo; P = 0.4). CONCLUSION: These results do not support the clinical utility of galantamine HBr in the treatment of ADHD at the doses used in this pilot study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000204139.20417.8a

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 37

Metadata

Authors
Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., & Spencer, T.
Venue
Journal of Clinical Psychopharmacology
Published
2006-04
Volume
26
Issue
2
Pages
163-166
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2076526042
Cited by
37
References
4
FWCI
0.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study. https://app.cochat.ai/papers/10.1097/01.jcp.0000204139.20417.8a
The paper
Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., & Spencer, T. (2006). A Double-blind Comparison of Galantamine Hydrogen Bromide and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder: A Pilot Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000204139.20417.8a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.